286Lu Adenocarcinoma p/w Pneumonia and Lymphangitis Carcinomatosa

  • 50 year old female from Africa
    • never smoker
    • worsening productive cough and exertional shortness of breath for the past 2 months
    • past medical history of
      • essential hypertension, obesity, GERD,
      • COVID-19 infection 3 months prior
    • Clinical
      • not febrile, respiratory rate 36, saturating 94% normal.
    • Labs
        • WBC 6.9, hemoglobin 10.5
        • alkaline phosphatase 148.
        • HIV negative.
        • CTPA showed no PE, diffuse patchy opacities with lower lobe predominance concerning for multifocal pneumonia versus miliary tuberculosis,
        • Right adrenal mass,
        • hypodense lesions are seen throughout the
          • thoracic spine and sternum
          • concerning for malignancy/metastatic disease.
          • spine MRI showed
            • numerous vertebral metastatic lesions in the cervical, thoracic, and lumbar spine as well as the pelvis. N
              • No extension of these lesions into the spinal canal or neural foramina.
              • No cord compression.
              • ? metastases in the cerebellum.
      • adenocarcinoma  likely has a targetable mutation that would change her prognosis with targeted therapy.
    • Stage IVB, cT4, cN2, cM1c, PD-L1; 0%,
      • NGS: RET fusion (KIF5B).
      • RX with Selpercatinib and Zometa
        • given presence of RET fusion
    • 4 months later
      • had to change immunotherapy to Xgeva,(DENOSUMAB) (severe arthralgias to prior immunotherapy)
      • status post Whole Brain XRT
      • Immunotherapy  Selpercatinib
    • 7 months later
      • PET CT
        • Complete metabolic response to treatment in this patient with history of
          stage IV lung adenocarcinoma.
        • No hypermetabolic activity in a residual left lower lobe shrinking
        • ill-defined 16 x 17 mm pulmonary nodule or rounded atelectasis ,
        • improvement of previously hypermetabolic lytic
          lesions
      • MRI Brain
      •  interval increase in enhancement and edema
      •  likely secondary to postradiation changes.